Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- (-) Clinical Pathways
- (-) Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- (-) Understanding Health Spending
- (-) Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Display Only
Showing 57 Results
NPC’s New Leader: Merging Research and Data with Real-World Experience
NPC Board Chair Michael Ryan says John M. O’Brien’s arrival as the new president and CEO of NPC reinforces a vital role the biopharmaceutical industry can play in the ongoing debate about health care…
Health Budgets Should Cap Patient Harm
An NPC-RTI study provides guidance on quality metrics and practices that can help decision makers understand which budget cap features have the potential to lessen the impact on patient health and…
AMCP Partnership Forum: Preparing for and Managing Rare Diseases
Stakeholders met virtually for an AMCP Partnership Forum to discuss viable solutions to challenges facing people living with rare disorders, such as affordable and timely access to therapies,…
The Dollar or Disease Burden: Caps on Healthcare Spending May Save Money, but at What “Cost” to Patients?
This study assessed the potential effects of budget caps design on disease burden and cost savings to help budget decision makers understand which budget cap features minimize impact to patient…
Stakeholders Find Step Therapy Should Be Evidence-Based, Flexible and Transparent: Assessing Appropriateness Using a Consensus Approach
Stakeholders disagree on when step therapy is appropriate, but agree on a set of criteria about how to develop, implement, communicate, safeguard and evaluate step therapy protocols.
If You Must Do Step Therapy, Do It Right
Finding consensus among health care stakeholders is never easy, and that is certainly true when it comes to the use of care management tools. But there are areas of agreement, especially if we focus…
Considering the Future Impact of COVID on Health Spending
AcademyHealth and the National Pharmaceutical Council hosted a salon examining the impact of the pandemic on health spending and resulting challenges to our health care system.
Digging Deeper Into Health Spending Data
NPC looks at AHIP's annual “Your Health Care Dollar” analysis, providing proper context and data behind the numbers.
Tackling the Real Drivers of Health Spending
A new Kaiser Family Foundation analysis examined 2018 health spending per capita in the United States compared to economically similar countries. The researchers found that outpatient and inpatient…
Why the Benefits of Medicines – Not Just Costs – Must Be a Part of the Conversation
NPC's Dr. Dubois discusses a Health Affairs article identifying public health efforts and pharmaceuticals as leading drivers impacting increased life expectancy in the U.S. between 1990 and 2015.
AARDA’s Randy Rutta Talks Step Therapy
In this Q&A, Randy Rutta, AARDA’s President and CEO, talks about his organization’s efforts to raise awareness about step therapy and opportunities for patient-centered reforms.
Lessons from COVID-19: Step Therapy Should Not Be a Barrier to Patient Access
Step therapy requires patients to try a clinically recognized, lower cost first-line therapy before receiving reimbursement for an alternative therapy prescribed by the physician and can delay access…
NPC Statement on Racial, Social Injustices and Health Disparities
The recent deaths of George Floyd, Ahmaud Arbery and Breonna Taylor have put a spotlight on the racial and social injustices that are unfortunately pervasive in the United States. The COVID-19…
Experts Advise Including Productivity in Value Assessment Frameworks – When Included, It Can Make a Difference
NPC researchers sought to assess if productivity is included in VAF analyses, when included, does it change the value assessment of an intervention, and if including productivity could change health…
What's It Like to Be an NPC Fellow?
Our current and previous fellows share some inside tips
Second National Pharmaceutical Council and Health Affairs Forum to Explore Emerging Health Spending Solutions
NPC, Health Affairs and several Going Below The Surface Forum partners on Sept. 11 are hosting a discussion among health policy experts on emerging solutions to rising U.S. health spending
U.S. Care Pathways: Continued Focus on Oncology and Outstanding Challenges
A peer-reviewed study assessed changes in development, implementation, and evaluation of care pathways, and reviewed the latest evidence on integration of pathways with value-based care initiatives…
NPC in Chain Drug Review: The Long-term Health Benefits of Biopharmaceuticals
In his latest column for Chain Drug Review, National Pharmaceutical Council (NPC) President and Chief Executive Officer Dan Leonard highlights the importance of taking a holistic view of health care…
Reconciling the Seemingly Irreconcilable: How Much Are We Spending on Drugs?
In this study from the National Pharmaceutical Council and IQVIA, researchers developed a model to understand the underlying methodological inputs that drive the substantial variation in drug…